Trial Profile

A Phase II Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PEERS

Most Recent Events

10 Apr 2025 Planned number of patients changed from 85 to 46.
08 Nov 2022 Status changed from not yet recruiting to recruiting.
18 Aug 2022 Planned initiation date changed from 30 Jul 2022 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com